Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30532481 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL2305506 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29872206 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL120613 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29907877 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29928500 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30951908 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30951920 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30951921 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL31369506 | 0.91 | MDM4 (0.52) | MDM4TP53SLC17A5MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2176250-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | MDM4 732/4885TP53 3886/4885SLC17A5 1999/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | MDM4 2519/4885TP53 1746/4885SLC17A5 2645/4885 |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MDM4 2864/4885TP53 2434/4885SLC17A5 2803/4885 |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | MC4R, MC5R, MC1R | MDM4 4865/4885TP53 4639/4885SLC17A5 3775/4885 |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | MC4R, MC5R, MC3R | MDM4 4876/4885TP53 4792/4885SLC17A5 2516/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885SLC17A5 4507/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | MDM4 2519/4885TP53 1746/4885SLC17A5 2645/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MDM4 2509/4885TP53 2046/4885SLC17A5 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.